Skip to main content
Signal8

BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

$BCLIPress releaseMay 15, 2026, 4:05 PM ETRead the release

BrainStorm Cell Therapeutics reported a Q1 2026 net loss of $2.1 million, with cash reserves dwindling to approximately $0.2 million as of March 31. The company highlighted its preparation for the Phase 3b ENDURANCE trial of NurOwn for ALS, noting that site activation and regulatory engagement are progressing but remain contingent on securing necessary financing.

Key figures

Net Loss
2127000
Revenue
0
Offering Price
0.95
Shares Offered
210526
Ga Expense
1284000
Rd Expense
762000
Warrants Issued
252630
Warrant Exercise Price
1.45

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.